Overview

MOSAIC - Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer

Status:
Completed
Trial end date:
2003-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the FOLFOX regimen versus LV5FU2 in the adjuvant treatment of stage II and III colon cancer. Primary objective: Disease Free Survival (DFS) Secondary objective: Overall Survival (OS), safety (including long term toxicity)
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Oxaliplatin